drugset
drugset / Trial / NCT02680418

Pharmacokinetics of FDL169 in Healthy Female Subjects

NCT02680418 ↗

Phase 1 Completed 8 enrolled Flatley Discovery Lab LLC
Non-randomizedSingle-groupOpen-label

Summary

To determine the pharmacokinetics of single and multiple doses of FDL169 in healthy female subjects.

Timeline

Start
2015-12
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FDL169 Small molecule — Oral

Indications

cystic fibrosis